The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 08, 2020

Filed:

Jan. 29, 2014
Applicants:

Biontech Ag, Mainz, DE;

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg—universitat Mainz Gemeinnutzige Gmbh, Mainz, DE;

Universitatsmedizin Der Johannes Gutenberg—universitat Mainz, Mainz, DE;

Jpt Peptide Technologies Gmbh, Berlin, DE;

Inventors:

Ugur Sahin, Mainz, DE;

Matin Daneschdar, Budenheim, DE;

Hans-Ulrich Schmoldt, Klein-Winternheim, DE;

Laura-Marie Kring (née Plum), Mainz, DE;

Markus Fiedler, Halle an der Saale, DE;

Ulf Reimer, Berlin, DE;

Karsten Schnatbaum, Berlin, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2019.01); A61K 38/12 (2006.01); C07K 5/00 (2006.01); A61K 38/04 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 14/705 (2006.01); C07K 7/64 (2006.01); A61K 39/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); A61K 38/08 (2013.01); A61K 38/12 (2013.01); A61K 39/0005 (2013.01); C07K 7/64 (2013.01); G01N 33/5308 (2013.01); G01N 33/57492 (2013.01); G01N 2333/705 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01);
Abstract

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.


Find Patent Forward Citations

Loading…